Skip to main content
SpringerLink
Log in

Evaluation of Acetylcholinesterase in an Animal Model of Maple Syrup Urine Disease

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Maple syrup urine disease is an inherited metabolic disease predominantly characterized by neurological dysfunction. However, the mechanisms underlying the neuropathology of this disease are still not defined. Therefore, the aim of this study was to investigate the effect of acute and chronic administration of a branched-chain amino acids (BCAA) pool (leucine, isoleucine, and valine) on acetylcholinesterase (AChE) activity and gene expression in the brain and serum of rats and to assess if antioxidant treatment prevented the alterations induced by BCAA administration. Our results show that the acute administration of a BCAA pool in 10- and 30-day-old rats increases AChE activity in the cerebral cortex, striatum, hippocampus, and serum. Moreover, chronic administration of the BCAA pool also increases AChE activity in the structures studied, and antioxidant treatment prevents this increase. In addition, we show a significant decrease in the mRNA expression of AChE in the hippocampus following acute administration in 10- and 30-day-old rats. On the other hand, AChE expression increased significantly after chronic administration of the BCAA pool. Interestingly, the antioxidant treatment was able to prevent the increased AChE activity without altering AChE expression. In conclusion, the results from the present study demonstrate a marked increase in AChE activity in all brain structures following the administration of a BCAA pool. Moreover, the increased AChE activity is prevented by the coadministration of N-acetylcysteine and deferoxamine as antioxidants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Chuang DT, Shih VE (2001) Maple syrup urine disease (branched-chain ketoaciduria). In: Scriver CR, Beaudt AL, Sly WL, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 1971–2005

    Google Scholar 

  2. Mackenzie DY, Woolf LI (1959) Maple syrup urine disease: an inborn error of the metabolism of valine, leucine, and isoleucine associated with gross mental deficiency. Br Med J 1:90–91

    Article  PubMed  CAS  Google Scholar 

  3. Zinnanti WJ, Lazovic J, Griffin K, Skvorak KJ, Paul HS, Homanics GE, Bewley MC, Cheng KC, Lanoue KF, Flanagan JM (2009) Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease. Brain 132:903–918

    Article  PubMed  Google Scholar 

  4. Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI (2002) Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics 109:999–1008

    Article  PubMed  Google Scholar 

  5. Schonberger S, Schweiger B, Schwahn B, Schwarz M, Wendel U (2004) Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. Mol Genet Metab 82:69–75

    Article  PubMed  CAS  Google Scholar 

  6. Tribble D, Shapira R (1983) Myelin proteins: degradation in rat brain initiated by metabolites causative of maple syrup urine disease. Biochem Biophys Res Commun 114:440–446

    Article  PubMed  CAS  Google Scholar 

  7. Snyderman SE, Norton PM, Roitman E, Holt LE Jr (1964) Maple syrup urine disease, with particular reference to dietotherapy. Pediatrics 34:454–472

    PubMed  CAS  Google Scholar 

  8. Danner DJ, Elsas LJ (1989) Disorders of branched chain amino acid and keto acid metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 671–692

    Google Scholar 

  9. Halestrap AP, Brand MD, Denton RM (1974) Inhibition of mitochondrial pyruvate transport by phenylpyruvate and a-ketoisocaproate. Biochem Biophys Acta 367:102–108

    Article  PubMed  CAS  Google Scholar 

  10. Howell RK, Lee M (1963) Influence of a-keto acids on the respiration of brain in vitro. Proc Soc Exp Biol Med 113:660–663

    PubMed  CAS  Google Scholar 

  11. Land JM, Mowbray J, Clark JB (1976) Control of pyruvate and beta-hydroxybutyrate utilization in rat brain mitochondria and its relevance to phenylketonuria and maple syrup urine disease. J Neurochem 26:823–830

    Article  PubMed  CAS  Google Scholar 

  12. Pilla C, Cardozo RF, Dutra-Filho CS, Wyse AT, Wajner M, Wannmacher CM (2003) Creatine kinase activity from rat brain is inhibited by branched-chain amino acids in vitro. Neurochem Res 28:675–679

    Article  PubMed  CAS  Google Scholar 

  13. Araújo P, Wassermann GF, Tallini K, Furlanetto V, Vargas CR, Wannmacher CM, Dutra-Filho CS, Wyse AT, Wajner M (2001) Reduction of large neutral amino acid levels in plasma and brain of hyperleucinemic rats. Neurochem Int 38:529–537

    Article  PubMed  Google Scholar 

  14. Wajner M, Vargas CR (1999) Reduction of plasma concentrations of large neutral amino acids in patients with maple urine disease during crises. Arch Dis Child 80:579

    Article  PubMed  CAS  Google Scholar 

  15. Wajner M, Coelho DM, Barschak AG, Araújo PR, Pires RF, Lulhier FL, Vargas CR (2000) Reduction of large neutral amino acid concentration in plasma and CSF of patients with maple syrup urine disease during crises. J Inherit Metab Dis 23:505–512

    Article  PubMed  CAS  Google Scholar 

  16. Appel SH (1966) Inhibition of brain protein synthesis: an approach to a biochemical basis of neurological dysfunction in the amino-acidurias. Trans N Y Acad Sci 29:63–70

    PubMed  CAS  Google Scholar 

  17. Taketomi T, Kunishita T, Hara A, Mizushima S (1983) Abnormal protein and lipid compositions of the cerebral myelin of a patient with maple syrup urine disease. Jpn J Exp Med 53:109–116

    PubMed  CAS  Google Scholar 

  18. Treacy E, Clow CL, Reade TR, Chitayat D, Mamer OA, Scriver CR (1992) Maple syrup urine disease: interrelationship between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination. J Inherit Metab Dis 15:121–135

    Article  PubMed  CAS  Google Scholar 

  19. Blokland A (1995) Acetylcholine: a neurotransmitter for learning and memory? Brain Res 21:285–300

    Article  CAS  Google Scholar 

  20. Fodale V, Quattrone D, Trecroci C, Caminiti V, Santamaria LB (2006) Alzheimer’s disease and anaesthesia: implications for the central cholinergic system. Br J Anaesth 97:445–452

    Article  PubMed  CAS  Google Scholar 

  21. Bartus RT, Dean RL 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–414

    Article  PubMed  CAS  Google Scholar 

  22. Mesulam MM (2004) The cholinergic innervation of the human cerebral cortex. Prog Brain Res 145:67–78

    Article  PubMed  Google Scholar 

  23. Das A, Dikshit M, Nath C (2001) Profile of acetylcholinesterase in brain areas of male and female rats of adult and old age. Life Sci 68:1545–1555

    Article  PubMed  CAS  Google Scholar 

  24. Descarries L, Gisiger V, Steriade M (1997) Diffuse transmission by acetylcholine in the CNS. Prog Neurobiol 53:603–625

    Article  PubMed  CAS  Google Scholar 

  25. Soreq H, Seidman S (2001) Acetylcholinesterase—new roles for an old actor. Nat Rev Neurosci 2:294–302

    Article  PubMed  CAS  Google Scholar 

  26. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S (2005) Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2:307–318

    Article  PubMed  CAS  Google Scholar 

  27. Metz CN, Tracey KJ (2005) It takes nerve to dampen inflammation. Nat Immunol 6:756–757

    Article  PubMed  CAS  Google Scholar 

  28. Zimmerman G, Soreq H (2006) Termination and beyond: acetylcholinesterase as a modulator of synaptic transmission. Cell Tissue Res 326:655–669

    Article  PubMed  CAS  Google Scholar 

  29. Silman I, Sussman JL (2005) Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology. Curr Opin Pharmacol 5:293–302

    Article  PubMed  CAS  Google Scholar 

  30. Aruoma OI, Halliwell B, Hoey BM, Butler J (1989) The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6:593–597

    Article  PubMed  CAS  Google Scholar 

  31. Moldeus P, Cotgreave IA, Berggren M (1986) Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 50:31–42

    PubMed  CAS  Google Scholar 

  32. Cotgreave IA (1997) N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 38:205–227

    Article  PubMed  CAS  Google Scholar 

  33. Sprong RC, Winkelhuyzen-Janssen AML, Aarsman CJM, van Oirschot JF, Bruggen T, van Asbeck BS (1998) Low-dose N-acetylcysteine protects rats against endotoxin-mediated oxidative stress, but high-dose increases mortality. Am J Respir Crit Care Med 157:1283–1293

    Google Scholar 

  34. Ritter C, Andrades ME, Reinke A, Menna-Barreto S, Moreira JC, Dal-Pizzol F (2004) Treatment with N-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis. Crit Care Med 32:342–349

    Article  PubMed  CAS  Google Scholar 

  35. Bridi R, Fontella FU, Pulrolnik V, Braun CA, Zorzi GK, Coelho D, Wajner M, Vargas CR, Dutra-Filho CS (2006) A chemically-induced acute model of maple syrup urine disease in rats for neurochemical studies. J Neurosci Methods 155:224–230

    Article  PubMed  CAS  Google Scholar 

  36. Di-Pietro PB, Dias ML, Scaini G, Burigo M, Constantino L, Machado RA, Dal-Pizzol F, Streck EL (2008) Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration. Neurosci Lett 434:139–143

    Article  PubMed  CAS  Google Scholar 

  37. Ellman GI, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95

    Article  PubMed  CAS  Google Scholar 

  38. Lowry OH, Rosebough NG, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275

    PubMed  CAS  Google Scholar 

  39. da Silva RS, Richetti SK, da Silveira VG, Battastini AM, Bogo MR, Lara DR, Bonan CD (2008) Maternal caffeine intake affects acetylcholinesterase in hippocampus of neonate rats. Int J Dev Neuroscience 26:339–343

    Article  Google Scholar 

  40. Amaral AU, Leipnitz G, Fernandes CG, Seminotti B, Schuck PF, Wajner M (2010) Alpha-ketoisocaproic acid and leucine provoke mitochondrial bioenergetic dysfunction in rat brain. Brain Res 1324:75–84

    Article  PubMed  CAS  Google Scholar 

  41. Ribeiro CA, Sgaravatti AM, Rosa RB, Schuck PF, Grando V, Schmidt AL, Ferreira GC, Perry ML, Dutra-Filho CS, Wajner M (2008) Inhibition of brain energy metabolism by the branched-chain amino acids accumulating in maple syrup urine disease. Neurochem Res 33:114–124

    Article  PubMed  CAS  Google Scholar 

  42. Sgaravati AM, Rosa RB, Schuck PF, Ribeiro CAJ, Wannmacher CMD, Wyse ATS, Dutra-Filho CS, Wajner M (2003) Inhibition of brain energy metabolism by the a-keto acids accumulating in maple syrup urine disease. Biochim Biophys Acta 1639:232–238

    Google Scholar 

  43. Barschak AG, Sitta A, Deon M, de Oliveira MH, Haeser A, Dutra-Filho CS, Wajner M, Vargas CR (2006) Evidence that oxidative stress is increased in plasma from patients with maple syrup urine disease. Metab Brain Dis 21:279–286

    Article  PubMed  CAS  Google Scholar 

  44. Bridi R, Araldi J, Sgarbi MB, Testa CG, Durigon K, Wajner M, Dutra-Filho CS (2003) Induction of oxidative stress in rat brain by the metabolites accumulating in maple syrup urine disease. Int J Dev Neurosci 21:327–332

    Article  PubMed  CAS  Google Scholar 

  45. Bridi R, Braun CA, Zorzi GK, Wannmacher CM, Wajner M, Lissi EG, Dutra-Filho CS (2005) Alpha-keto acids accumulating in maple syrup urine disease stimulate lipid peroxidation and reduce antioxidant defences in cerebral cortex from young rats. Met Brain Dis 20:155–167

    Article  CAS  Google Scholar 

  46. Bridi R, Latini A, Braun CA, Zorzi GK, Wajner M, Lissi EG, Dutra-Filho CS (2005) Evaluation of the mechanisms involved in leucine-induced oxidative damage in cerebral cortex of young rats. Free Radic Res 39:71–79

    Article  PubMed  CAS  Google Scholar 

  47. Fontella FU, Gassen E, Pulrolni V, Wannmacher CMD, Klein AB, Wajner M, Dutra-Filho CS (2002) Stimulation of lipid peroxidation in vitro in rat brain by the metabolites accumulating in maple syrup urine disease. Metab Brain Dis 17:47–54

    Article  PubMed  CAS  Google Scholar 

  48. Dodd PR, Williams SH, Gundlach AL, Harper PA, Healy PJ, Dennis JA, Johnston GA (1992) Glutamate and gamma-aminobutyric acid neurotransmitter systems in the acute phase of maple syrup urine disease and citrullinemia encephalopathies in newborn calves. J Neurochem 59:582–590

    Article  PubMed  CAS  Google Scholar 

  49. Prensky AL, Moser HW (1967) Changes in the amino acid composition of proteolipids of white matter during maturation of the human nervous system. J Neurochem 14:117–121

    Article  PubMed  CAS  Google Scholar 

  50. Tavares RG, Santos CEF, Tasca C, Wajner M, Souza DO, Dutra-Filho CS (2000) Inhibition of glutamate uptake into synaptic vesicles of rat brain by the metabolites accumulating in maple syrup urine disease. J Neurol Sci 181:44–49

    Article  PubMed  CAS  Google Scholar 

  51. Yudkoff M, Daikhin Y, Lin ZP, Nissim I, Stern J, Pleasure D, Nissin I (1994) Interrelationships of leucine and glutamate metabolism in cultured astrocyts. J Neurochem 62:1192–1202

    Article  PubMed  CAS  Google Scholar 

  52. Mello CF, Feksa L, Brusque AM, Wannmacher CM, Wajner M (1999) Chronic early leucine administration induces behavioral deficits in rats. Life Sci 65:747–55

    Article  PubMed  CAS  Google Scholar 

  53. Tõugu V, Kesvatera T (1996) Role of ionic interactions in cholinesterase catalysis. Biochim Biophys Acta 1298:12–30

    Article  PubMed  Google Scholar 

  54. Greenfield S (1984) Acetylcholinesterase may have novel functions in the brain. Trends Neurosci 7:364–368

    Article  CAS  Google Scholar 

  55. Inestrosa NC, Alvarez A, Pérez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J (1996) Acetylcholinesterase accelerates assembly of amyloid-b-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 16:881–891

    Article  PubMed  CAS  Google Scholar 

  56. Karpel R, Sternfeld M, Ginzberg D, Guhl E, Graessmann A, Soreq H (1996) Overexpression of alternative human acetylcholinesterase forms modulates process extensions in cultured glioma cells. J Neurochem 66:114–123

    Article  PubMed  CAS  Google Scholar 

  57. Layer P, Willbold E (1995) Novel functions of cholinesterases in development, physiology and disease. Prog Hisotchem Cytochem 29:1–92

    CAS  Google Scholar 

  58. Jiang H, Zhang XJ (2008) Acetylcholinesterase and apoptosis. A novel perspective for an old enzyme. FEBS J 275:612–617

    Article  PubMed  CAS  Google Scholar 

  59. Ben-Ari S, Toiber D, Sas AS, Soreq H, Ben-Shaul Y (2006) Modulated splicing-associated gene expression in P19 cells expressing distinct acetylcholinesterase splice variants. J Neurochem 97:24–34

    Article  PubMed  CAS  Google Scholar 

  60. Park SE, Kim ND, Yoo YH (2004) Acetylcholinesterase plays a pivotal role in apoptosome formation. Cancer Res 64:2652–2655

    Article  PubMed  CAS  Google Scholar 

  61. Jouvet J, Rustin P, Taylor DL, Pocock JM, Felderhoff-Mueser U, Mazarakis ND, Sarraf C, Joashi U, Kozma M, Greenwood K, Edwards AD, Mehmet H (2000) Branched chain amino acids induce apoptosis in neural cells without mitochondrial membrane depolarization or cytochrome c release: implications for neurological impairment associated with maple syrup urine disease. Mol Biol Cell 11:1919–1932

    PubMed  CAS  Google Scholar 

  62. Krishna S, Andersson AM, Semsey S, Sneppen K (2006) Structure and function of negative feedback loops at the interface of genetic and metabolic networks. Nucleic Acids Res 34:2455–2462

    Article  PubMed  CAS  Google Scholar 

  63. Keseler IM, Collado-Vides J, Gama-Castro S, Ingraham J, Paley S, Paulsen IT, Peralta-Gil M, Karp PD (2005) EcoCyc: a comprehensive database resource for Escherichia coli. Nucleic Acids Res 1:334–337

    Google Scholar 

  64. Salgado H, Santos-Zavaleta A, Gama-Castro S, Millan-Zarate D, Diaz-Peredo E, Sanchez-Solano F, Perez-Rueda E, Bonavides-Martinez C, Collado-Vides J, Regulon DB (2001) RegulonDB (version 3.2): transcriptional regulation and operon organization in Escherichia coli K-12. Nucleic Acids Res 29:72–74

    Article  PubMed  CAS  Google Scholar 

  65. Grifman M, Arbel A, Ginzberg D, Glick D, Elgavish S, Shaanan B, Soreq H (1997) In vitro phosphorylation of acetylcholinesterase at non-consensus protein kinase A sites enhances the rate of acetylcholine hydrolysis. Brain Res Mol Brain Res 51:179–87

    Article  PubMed  CAS  Google Scholar 

  66. Aitken RJ, Harkiss D, Knox W, Paterson M, Irvine DS (1998) A novel signal transduction cascade in capacitating human spermatozoa characterized by a redox-regulated, cAMP-mediated induction of tyrosine phosphorylation. J Cell Sci 111:645–656

    PubMed  CAS  Google Scholar 

  67. Herrero MB, Chatterjee S, Lefièvre L, de Lamirande E, Gagnon C (2000) Nitric oxide interacts with the cAMP pathway to modulate capacitation of human spermatozoa. Free Radic Biol Med 29:522–536

    Article  Google Scholar 

  68. Leclerc P, de Lamirande E, Gagnon C (1997) Regulation of protein tyrosine phosphorylation and human sperm capacitation by reactive oxygen species derivatives. Free Radic Biol Med 22:643–656

    Article  PubMed  CAS  Google Scholar 

  69. Aldunate R, Casar JC, Brandan E (2004) Structural and functional organization of synaptic acetylcholinesterase. Brain Res Rev 47:96–104

    Article  PubMed  CAS  Google Scholar 

  70. Melo JB, Agostinho P, Oliveira CR (2003) Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci Res 45:117–127

    Article  PubMed  CAS  Google Scholar 

  71. Benzi G, Morreti A (1998) Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer’s disease? Eur J Pharmacol 346:1–13

    Article  PubMed  CAS  Google Scholar 

  72. Das A, Shanker G, Nath C, Pal R, Singh S, Singh HK (2002) A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav 73:893–900

    Article  PubMed  CAS  Google Scholar 

  73. Grisaru D, Sternfeld M, Eldor A, Glick D, Soreq H (1999) Structural roles of acetylcholinesterase variants in biology and pathology. Eur J Biochem 264:672–686

    Article  PubMed  CAS  Google Scholar 

  74. Kaur T, Pathak CM, Pandhi P, Khanduja KL (2007) Effects of green tea extract on learning, memory, behavior and acetylcholinesterase activity in young and old male rats. Brain Cogn 67:25–30

    Article  PubMed  Google Scholar 

  75. Mesulam MM, Guillozet A, Shaw P, Levey A (2002) Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110:627–639

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by grants from Programa de Pós-graduação em Ciências da Saúde—Universidade do Extremo Sul Catarinense and Conselho Nacional de Desenvolvimento Científico e Tecnológico.

Author information

Authors and Affiliations

  1. Laboratório de Bioenergética, Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Av. Universitária, 1105, Criciúma, 88806-000, Santa Catarina, Brazil

    Giselli Scaini, Natália de Rochi, Isabela C. Jeremias & Emilio L. Streck

  2. Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, Rio Grande de Sul, Brazil

    Giselli Scaini, Natália de Rochi, Isabela C. Jeremias, Pedro F. Deroza, Alexandra I. Zugno, Talita C. B. Pereira, Giovanna M. T. Oliveira, Luiza W. Kist, Maurício R. Bogo & Emilio L. Streck

  3. Laboratório de Neurociências, Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, Santa Catarina, Brazil

    Pedro F. Deroza & Alexandra I. Zugno

  4. Laboratório de Biologia Genômica e Molecular, Departamento de Biologia Celular e Molecular, Faculdade de Biociências, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

    Talita C. B. Pereira, Giovanna M. T. Oliveira, Luiza W. Kist & Maurício R. Bogo

  5. Laboratório de Erros Inatos do Metabolismo, Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, Santa Catarina, Brazil

    Patrícia F. Schuck & Gustavo C. Ferreira

Authors
  1. Giselli Scaini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natália de Rochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabela C. Jeremias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pedro F. Deroza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexandra I. Zugno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Talita C. B. Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giovanna M. T. Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Luiza W. Kist
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maurício R. Bogo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Patrícia F. Schuck
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gustavo C. Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Emilio L. Streck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emilio L. Streck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scaini, G., de Rochi, N., Jeremias, I.C. et al. Evaluation of Acetylcholinesterase in an Animal Model of Maple Syrup Urine Disease. Mol Neurobiol 45, 279–286 (2012). https://doi.org/10.1007/s12035-012-8243-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-012-8243-3

Keywords

Search

Navigation